[exclusive] in 2017, the performance of listed pharmaceutical companies took the lead: the net profit of four companies exceeded 1 billion, and the performance of Zhifei biology, Laimei and Yisheng took off

2017's pharmaceutical industry is a year of rapid development New policies are constantly changing, new demands are constantly raised, and new technologies are constantly discovered The pharmaceutical industry is drifting in the long sea of the new era In this process, some enterprises seek to become new and develop steadily, some enterprises March bravely to meet the vigorous state, and some enterprises are experiencing the waves and reefs Let's take a look at the achievements of these enterprises in 2017 According to incomplete statistics, as of February 28, 2018, nearly 100 pharmaceutical listed companies have published the 2017 annual performance express, and the key performance data are shown in Table 1 Table 1 2017 performance express of pharmaceutical listed companies 1 Net profit of 4 enterprises exceeds 1 billion Among the nearly 100 companies that have published the performance express, four have a net profit of more than 1 billion, which are XinHeCheng, xinlitai, Yifan pharmaceutical and Ruikang pharmaceutical Their net profit is not much different from that of the previous article "2017 performance forecast of pharmaceutical listed companies, the net profit of these companies is expected to be more than 1 billion", which is 1.702 billion, 1.452 billion, 1.322 billion and 1.009 billion, respectively, with a year-on-year increase The length is 41.55%, 3.98%, 87.53%, 70.78% (as shown in Table 2) Table 2 in 2017, the net profit of pharmaceutical listed companies reached 1 billion enterprises Among the 11 enterprises whose net profit growth exceeded 100% and the published performance express, 11 enterprises' net profit growth exceeded 100% The achievements of these enterprises in 2017 are worthy of affirmation This is a good step for their sustainable development, which needs to be maintained in the future It is worth mentioning that nearly half of these 11 enterprises are biological products enterprises, and the performance of Zhifei biology, Rhine biology, Huayuan biology, sannuo biology and Tianshan biology increased dramatically in 2017 In recent years, the rapid development of biological products has gradually become a hot topic The market demand of biological products has driven the rapid development of biological medicine industry According to the pharmaceutical intelligence data, the overall trend of the number of undertakers of biological products (including treatment and prevention) for CDE in the past 10 years is on the rise, reaching the maximum in 2017, with 616 (calculated by acceptance number, the same below), including 193 new drugs, which is also the largest number in several years Table 3 in 2017, Chongqing Zhifei Biological Products Co., Ltd (hereinafter referred to as "Zhifei biological"), a private biological vaccine enterprise with a year-on-year growth of more than 100% in net profit of pharmaceutical listed companies, achieved a net profit of 432 million in 2017, a year-on-year growth of 1229.25%, which is currently the company with the largest growth in business performance Zhifei biology is a company engaged in the research, development, production and sales of vaccines and biological products It is one of the private biological vaccine enterprises with strong comprehensive strength in China, and also one of the few domestic manufacturers with rich independent vaccine product series Its vaccine product sales volume has long ranked first among private vaccine enterprises The main products on the market are 23 valent pneumococcal polysaccharide vaccine, inactivated hepatitis A vaccine, tetravalent human papillomavirus vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type B vaccine, etc In 2017, the net profit of Chongqing Laimei Pharmaceutical Co., Ltd (hereinafter referred to as "Laimei pharmaceutical") reached 65.22 million yuan, an increase of 834.29% year on year Laimei Pharmaceutical Co., Ltd is a scientific and technological pharmaceutical enterprise mainly engaged in research and development, production and sales of quinolones anti infectives, anti-tumor drugs and parenteral nutrition drugs The company's products mainly cover two series of anti infectives and specialty drugs, including quinolones anti infectives, anti-tumor drugs, parenteral nutrition drugs, etc In the development of Laimei pharmaceutical industry for many years, it has its own excellent R & D ability and market promotion ability According to drug intelligence data, Laimei pharmaceutical has 129 new drug applications in CDE (calculated by acceptance number, the same below), including 32 approved for production and 25 approved for clinical application In addition, there are three new drugs of category 1 (as shown in the figure below) And in the market, Laimei pharmaceutical has 52 drug varieties winning the bid in 31 regions, with a certain market share Laimei has a good development situation in recent years, and 2018 is expected to have better performance Jilin Ji'an Yisheng Pharmaceutical Co., Ltd (hereinafter referred to as "Yisheng pharmaceutical"), a star enterprise of Yisheng pharmaceutical, had a net profit of 6.03 million yuan in 2017, an increase of 354.99% year on year Yisheng pharmaceutical is an enterprise engaged in the R & D, production and sales of Chinese patent medicines Its main products include Shengmai injection, Zhenyuan capsule, Xinyue capsule, Qingkailing injection, Guifu Dihuang capsule, etc the treatment scope of the products is mainly cardiovascular and cerebrovascular diseases According to the company, Yisheng pharmaceutical can produce 11 dosage forms, with 116 varieties and 129 drug production approval numbers Among them, 51 varieties are listed in the national medical insurance catalogue, with 4 varieties protected by the state and 6 exclusive varieties According to drug intelligence data, YSD has applied for 63 drugs in CDE, including 7 new drugs, 15 chemical generic drugs, 10 approved for production and 1 approved for clinical use In recent two years, no new drug application has been made for Yisheng drug With the impact of the new deal, Yisheng pharmaceutical still needs to develop multiple product lines in the future to maintain the good development of Chinese patent medicine 3、 According to the data of the published performance express, the net profit of 16 enterprises decreased year-on-year, among which Boji pharmaceutical and Jiaying pharmaceutical had more severe losses, and their net profit was negative in 2017 Longjin pharmaceutical, Yuheng pharmaceutical and Shanghai Laishi also suffered a net profit loss of about 50% Although other enterprises have a certain degree of loss, but the range is not very large Table 4 in 2017, Boji pharmaceutical and Jiaying Pharmaceutical Co., Ltd., the enterprises whose net profit decreased on a year-on-year basis, Guangzhou Boji Pharmaceutical Biotechnology Co., Ltd is a large-scale high-tech enterprise group dedicated to research and development services of new drugs, health care products, cosmetics and other health-related products According to the company's performance in 2017, during the reporting period, the progress of clinical research service business project was restored, the main business income achieved a large growth, and the company's total operating income increased by 81.97% over the same period of last year; however, due to the increase of the cost of clinical research project, the company increased the investment in independent research and development projects, as well as the investment in the construction and trial operation of GLP laboratory platform of drug evaluation center of the company Line and certification applications, etc., leading to the increase in the cost of the period As a result, the performance decreased and the net profit decreased significantly Guangdong Jiaying Pharmaceutical Co., Ltd is a professional Chinese medicine manufacturer integrating R & D, production and sales, with its own core technology of intellectual property rights At present, it has 5 dosage forms and more than 60 varieties, with an annual extraction capacity of nearly 10000 tons and a design production capacity of nearly 500 million yuan The company said that the decline in performance was mainly due to a significant decline in the performance of its wholly-owned subsidiary Hunan Jinsha Pharmaceutical Co., Ltd (hereinafter referred to as "Jinsha pharmaceutical") in 2017 due to changes in market environment, industrial policies and other factors According to the relevant requirements of the accounting standards for Business Enterprises No 8 - impairment of assets on the treatment of goodwill impairment, in order to present the financial statements prudently and fairly, the company accrues the impairment provision for the goodwill generated from the acquisition of 64.466% of the shareholders' equity of Jinsha Pharmaceutical Co., Ltd., with the amount of 98.16 million yuan As a result, the net profit attributable to the shareholders of the listed company in the current year is at a loss Shanghai Laishi is expected to be flat but is now losing money According to the previous quarterly profit of Shanghai Laishi, the company's performance is expected to be the same in the same period, about 1 billion yuan However, according to the 2017 performance express, the company's profit has lost The main reasons explained by the company are as follows: 1 The subsidiary Zhengzhou Laishi stopped production in the middle of 2017 in order to expand production capacity, carried out technical transformation on relevant production facilities, affected the production of products, and affected the current operating revenue 。 2 In 2017, the pharmaceutical industry implemented the "two vote system", and the promotion of the "two vote system" has a certain impact on the company's operating revenue in 2017 in the short term 3 Due to the fluctuation of stock price, the income from changes in fair value and investment income generated by securities investment in 2017 were significantly reduced compared with the same period of last year It can be seen from the loss situations of the above companies that, on the one hand, the loss of net profit is related to the general situation of policies in a macro sense Many enterprises should interpret the policies in a timely manner, follow the general direction of policies, and be ready for change before they can meet the trend of development; on the other hand, it is due to the influence of their own company's strategic implementation and objective situation, which also requires enterprises to make planning preparations in advance and be tight after the event We need to deal with it urgently and avoid some risks before it can develop steadily Data source: Yaozhi data, tonghuashun